One in eight Americans is already on a GLP-1. Within the next 12 to 24 months, that number could jump to one in two. And most people have no idea where these drugs actually come from — or what's really in them. In this episode of Cut to the Chase: with Gregg Goldfarb, Gregg sits down with Fabian Calvo — longevity industry insider, pharmaceutical supply chain strategist, and CEO of WellSync — to pull back the curtain on the global drug supply chain, the real science behind peptides and testosterone therapy, and what it actually takes to live a longer, healthier life. If you've ever taken a medication, wondered about GLP-1s, or heard about peptides and had no idea where to start — this episode is essential listening. Join Gregg and Fabian on Cut to the Chase as they discuss: Why 95% of America's generic drugs are manufactured in China and India — and what that means for national security What a peptide actually is, why GLP-1s like Ozempic and Wegovy are just the beginning, and how to know if your source is safe The truth about testosterone therapy — why decades of fear were based on bad science, and what the latest research actually shows What NAD does, what rapamycin is, and which longevity treatments have real science behind them Why the U.S. spends trillion a year on chronic disease — and what blue zone cultures are doing differently How pharmacy benefit managers are driving up drug prices for everyday Americans What medicine will look like in 10 years — and the three things you can do right now to be ready KEY MOMENTS 00:00 — GLP-1s, peptides, and why this conversation matters right now 01:30 — How the pharmaceutical supply chain actually works 03:00 — Why 95% of generic drugs come from China and India 05:00 — What is a peptide? The simplest explanation you'll hear 07:30 — BPC-157, the "Wolverine stack," and what the science says 10:00 — Fabian's background: from real estate to pharmaceutical supply chain CEO 13:00 — The broken U.S. healthcare model and the chronic disease epidemic 16:00 — Female hormone therapy: the NIH study that was completely debunked 19:00 — Testosterone therapy: what's changed, what's FDA-approved, and who it's for 22:00 — NAD, NMN, and Dr. David Sinclair's research explained 25:00 — Rapamycin, Easter Island, and the most exciting longevity drug you've never heard of 29:00 — Blue zones, Japan, and why community might be the best longevity medicine 33:00 — America's drug supply at geopolitical risk — what's being done 37:00 — Why Americans pay more for drugs than any other country 40:00 — Pharmacy benefit managers explained — and why they're a problem 44:00 — What medicine looks like in 10 years and the three pillars to start with today Fabian Calvo is a longevity industry insider and pharmaceutical supply chain strategist with over a decade of experience at the intersection of drug regulation, compound pharmacy networks, and healthcare access. He is the founder of New Care Pharmaceuticals, an FDA-compliant importer of active pharmaceutical ingredients, and CEO and board member of WellSync, a tech infrastructure company whose platform Boom RX has been placed in over 10,000 medical clinics, med spas, and aesthetics practices across the United States. Fabian has met with FDA leadership including former FDA head Dr. Marty Makary, and has traveled extensively to China and India to vet pharmaceutical sourcing. His mission is to help people live healthier, longer lives through proactive, data-driven healthcare. The resources mentioned in this episode are: Learn more about WellSync and the Boom RX platform, currently active in over 10,000 medical clinics across the U.S.: wellsync.com Learn more about New Care Pharmaceuticals and FDA-compliant pharmaceutical ingredient sourcing. Research BPC-157 and its studied benefits for gut health, tendon repair, and inflammation — referenced in this episode as a widely researched peptide. Learn more about rapamycin and its longevity research, originally discovered on Easter Island (Rapa Nui) and now being studied for its mTOR-inhibiting and anti-aging properties. Research NAD and NMN supplementation and the work of Harvard PhD Dr. David Sinclair on mitochondrial function and aging. Consult your provider about a comprehensive blood panel that includes hormone levels — Fabian's recommended first step before starting any therapy. Learn more about GLP-1 medications including Ozempic and Wegovy and the compound pharmacy landscape for access and sourcing. Want to hear more health, legal, and lifestyle conversations that matter? Subscribe to Cut to the Chase: with Gregg Goldfarb. Want to stay updated on our latest podcasts? Subscribe to Cut to the Chase: Podcast Newsletter for monthly podcast releases and the latest legal news: https://lp.constantcontactpages.com/sl/KqDopgE